ID Davis - N# Eastern Health Clinical School, Monash University

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice

P. Grivas, E. Grande,I. D. Davis, H. H. Moon, M. -O. Grimm,S. Gupta, P. Barthelemy, C. Thibault, S. Guenther, S. Hanson,C. N. Sternberg

ESMO OPENno. 6 (2023): 102050-102050

引用0浏览0WOS引用

LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)

L. Emmett, S. Subramaniam, M. Crumbaker, A.M. Joshua, A.J. Weickhardt, S.T. Lee,S. Ng, R.J. Francis, J.C.H. Goh, D.A. Pattison, H. Tan, I.D. Kirkwood,

Annals of Oncology (2023): S1325-S1325

引用1浏览0引用

Association Of Ceramide Metabolism With Resistance To Androgen Receptor Signalling Inhibitors In Metastatic Prostate Cancer

Lin Hui-Ming,H-M. Lin, B. Mak,K. Huynh,E. M. Kwan,H. Fettke,B. Tran,I. D. Davis, K. L. Mahon,M. R. Stockler, K. Briscoe,G. M. Marx,

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY（2021）

引用0浏览0引用

Cisplatin (Cis)-Related Immunomodulation And Efficacy With Atezolizumab (Atezo) Plus Cis- Vs Carboplatin (Carbo)-Based Chemotherapy (Chemo) In Metastatic Urothelial Cancer (Muc)

M. D. Galsky,X. Guan,R. Banchereau,L. Wang, J. Zhu,H. Yu, D. Rishipathak, E. Hajaj, R. H. Herbst,I. D. Davis, E. Grande,A. Bamias,

ANNALS OF ONCOLOGY（2021）

引用9浏览0引用

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled …

T Niazi,S Williams,ID Davis,MR Stockler,AJ Martin,K Bracken

user-5f8cf9244c775ec6fa691c99（2021）

引用0浏览0引用

Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257))

S. Gillessen, A. Omlin, G. Attard,J. S. de Bono,E. Efstathiou, K. Fizazi, S. Halabi,P. S. Nelson, O. Sartor,M. R. Smith, H. R. Soule, H. Akaza,

user-5f8cf7e04c775ec6fa691c92（2019）

引用219浏览0引用

219

LBA56Primary efficacy analysis results from the SORCE trial (RE05): Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: An international, randomised double-blind phase III trial led by the MRC CTU at UCL

T Q G Eisen, E Frangou, B Smith,A Ritchie, R S Kaplan, B Oza,I D Davis,M R Stockler, L Albiges,B Escudier,J M G Larkin,A Bex,

ANNALS OF ONCOLOGY（2019）

引用11浏览0引用

Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology …

S Gillessen,A Omlin,G Attard,JS De Bono,E Efstathiou, K Fizazi,S Halabi, PS Nelson,O Sartor,MR Smith,HR Soule, H Akaza,

Annals of Oncology（2019）

引用0浏览0引用

LBA14_PRIMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)

E Grande, M Galsky,J A Arranz Arija,M De Santis,I D Davis,U F F De Giorgi, M Mencinger,E Kikuchi,X Garcia del Muro,M Gumus,M Özgüroğlu,A Rezazadeh Kalebasty,

Annals of Oncology（2019）

引用30浏览0引用

Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer …

S Williams,ID Davis,C Sweeney,MR Stockler,AJ Martin,W Hague

user-5fe1a78c4c775e6ec07359f9（2017）

引用1浏览0引用

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn